Retrospective Epidemiology Study Of ALK Rearrangement In Non-Small Cell Lung Cancer Patients In The Middle East & North Africa

NCT02304406

Last updated date
Study Location
National Cancer Institute
Cairo / Misr Al Qadimah, , , Egypt
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Non-small Cell Lung Cancer
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- 1. Histological confirmation of nonsquamous NSCLC, with any TNM stage. 2. Available and sufficient tissue sample for ALK testing 3.Tissue samples are less than 5 years old 4.Routinely processed formalin-fixed, paraffin-embedded tissue samples only (see exclusion criteria pertaining to tissue samples).

5.Histological sections mounted on glass slides must not be older than 3 months 6.Age > 18 years 7.Any ECOG Performance status 8.Still alive, or death confirmed before inclusion, or is unknown 9.Disease diagnosis and/or treatment in one of the centers, in the last 5 years, assigned to participate in the study; 10.Written informed consent for general investigational testing was previously obtained, or specifically obtained for this retrospective epidemiology study, or having a documented waiver for the Informed consent document use, as required by local regulatory authorities, &/or Research Ethics committee/Institutional Review Board.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- 1- Tumor tissue samples older than 5 year period or samples not properly stored.


2-Tumor tissue samples fixed by using AFA, B5, Bouin's, 95% ETOH, & alcohol fixatives.


3-Under-fixed tissue samples (i.e. < 6 hrs) 4-Tumor tissue samples that have been
subject to any decalcification processes. 5-Recycled paraffin-embedded tissue samples.
6-Cut slides stored longer than 3 months. 7-Insufficient tissue samples with less
tumor cells & high amount of necrosis.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Non-Small Cell Lung CancerARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer NCT01360554
  1. Birmingham, Alabama
  2. Birmingham, Alabama
  3. Birmingham, Alabama
  4. Florence, Alabama
  5. Mobile, Alabama
  6. Mobile, Alabama
  7. Muscle Shoals, Alabama
  8. Chandler, Arizona
  9. Chandler, Arizona
  10. Gilbert, Arizona
  11. Mesa, Arizona
  12. Mesa, Arizona
  13. Fayetteville, Arkansas
  14. Rogers, Arkansas
  15. Alhambra, California
  16. Alhambra, California
  17. Duarte, California
  18. Fullerton, California
  19. Los Angeles, California
  20. Los Angeles, California
  21. Los Angeles, California
  22. Los Angeles, California
  23. Los Angeles, California
  24. Los Angeles, California
  25. Los Angeles, California
  26. Los Angeles, California
  27. Los Angeles, California
  28. Los Angeles, California
  29. Pasadena, California
  30. Pasadena, California
  31. Redondo Beach, California
  32. Santa Maria, California
  33. Santa Monica, California
  34. Santa Monica, California
  35. Santa Monica, California
  36. South Pasadena, California
  37. Valencia, California
  38. Westlake Village, California
  39. Norwalk, Connecticut
  40. Orlando, Florida
  41. Orlando, Florida
  42. Orlando, Florida
  43. Orlando, Florida
  44. Port Saint Lucie, Florida
  45. Atlanta, Georgia
  46. Atlanta, Georgia
  47. Atlanta, Georgia
  48. Atlanta, Georgia
  49. Austell, Georgia
  50. Carrollton, Georgia
  51. Cartersville, Georgia
  52. Columbus, Georgia
  53. Decatur, Georgia
  54. Decatur, Georgia
  55. Decatur, Georgia
  56. Douglasville, Georgia
  57. Duluth, Georgia
  58. Gainesville, Georgia
  59. Gainesville, Georgia
  60. Gainesville, Georgia
  61. Lawrenceville, Georgia
  62. Marietta, Georgia
  63. Snellville, Georgia
  64. Arlington Heights, Illinois
  65. Harvey, Illinois
  66. Harvey, Illinois
  67. Harvey, Illinois
  68. Niles, Illinois
  69. Tinley Park, Illinois
  70. Evansville, Indiana
  71. Munster, Indiana
  72. Waterloo, Iowa
  73. Hazard, Kentucky
  74. Louisville, Kentucky
  75. Louisville, Kentucky
  76. Louisville, Kentucky
  77. Detroit, Michigan
  78. Farmington Hills, Michigan
  79. Starkville, Mississippi
  80. Tupelo, Mississippi
  81. Creve Coeur, Missouri
  82. Saint Louis, Missouri
  83. Saint Louis, Missouri
  84. Saint Peters, Missouri
  85. Lebanon, New Hampshire
  86. Denville, New Jersey
  87. Stony Brook, New York
  88. Hickory, North Carolina
  89. Lenoir, North Carolina
  90. Norman, Oklahoma
  91. Oklahoma City, Oklahoma
  92. Oklahoma City, Oklahoma
  93. Corvallis, Oregon
  94. Corvallis, Oregon
  95. Corvallis, Oregon
  96. Lincoln City, Oregon
  97. Newport, Oregon
  98. Sayre, Pennsylvania
  99. Sayre, Pennsylvania
  100. Longview, Texas
  101. Tyler, Texas
  102. Waco, Texas
  103. Kennewick, Washington
  104. Richland, Washington
  105. Richland, Washington
  106. Seattle, Washington
  107. Seattle, Washington
  108. Vienna,
  109. Brussels,
  110. Brussels,
  111. Charleroi,
  112. Mons,
  113. Roeselare,
  114. Nanning, Guangxi
  115. Wuhan, Hubei
  116. Changchun, Jilin
  117. Chengdu, Sichuan
  118. Shanghai,
  119. Aalborg,
  120. Helsinki,
  121. Pori,
  122. Dijon,
  123. Grenoble cedex 09,
  124. Paris,
  125. Poitiers Cedex,
  126. Saint Herblain cedex,
  127. Aachen,
  128. Gauting,
  129. Immenhausen,
  130. Mainz,
  131. Moers,
  132. Larissa, Thessaly
  133. Athens,
  134. Heraklion,
  135. Budapest,
  136. Debrecen,
  137. Farkasgyepu,
  138. Gyula,
  139. Nyiregyhaza,
  140. Zalaegerszeg-Pozva,
  141. Ahmedabad, Gujarat
  142. Bangalore, Karnataka
  143. Mumbai, Maharashtra
  144. Pune, Maharastra
  145. Dublin, Leinster
  146. Dublin, Leinster
  147. Dublin,
  148. Waterford,
  149. Nagoya, Aichi
  150. Kashiwa, Chiba
  151. Matsuyama-city, Ehime
  152. Asahikawa, Hokkaido
  153. Akashi, Hyogo
  154. Kanazawa city, Ishikawa
  155. Yokohama, Kanagawa
  156. Sendai, Miyagi
  157. Kurashiki, Okayama
  158. Okayama-city, Okayama
  159. Sakai-Shi, Osaka-fu
  160. Osaka-city, Osaka
  161. Osakasayama-shi, Osaka
  162. Sunto-gun, Shizuoka
  163. Chuo-Ku, Tokyo
  164. Ube-shi, Yamaguchi
  165. Fukuoka,
  166. Fukuoka,
  167. Fukuoka,
  168. Koto-ku, Tokyo,
  169. Seoul,
  170. Seoul,
  171. Seoul,
  172. Oaxaca,
  173. Otwock, Mazowieckie
  174. Otwock, Mazowieckie
  175. Warsaw, Mazowieckie
  176. Warsaw, Mazowieckie
  177. Krasnodar, Krasnodarskij Kraj
  178. Sochi, Krasnodarskij Kraj
  179. Pyatigorsk, Stavropolskij Kraj
  180. Pyatigorsk,
  181. Saint-Petersburg,
  182. Saint-Petersburg,
  183. Saint-Petersburg,
  184. Saint-Petersburg,
  185. Saint-Petersburg,
  186. Saint-Petersburg,
  187. Saint-Petersburg,
  188. Samara,
  189. Bratislava,
  190. Nitra,
  191. Nove Zamky,
  192. Parktown,Johannesburg, Gauteng
  193. Kraaifontein, Western Cape
  194. Bloemfontein,
  195. Port Elizabeth,
  196. Elche, Alicante
  197. Badalona, Barcelona
  198. Castellón, Castellon
  199. Barcelona,
  200. Barcelona,
  201. Barcelona,
  202. Barcelona,
  203. Barcelona,
  204. Barcelona,
  205. Castellon,
  206. Madrid,
  207. Madrid,
  208. Madrid,
  209. Sevilla,
  210. Karlstad,
  211. Stockholm,
  212. Aarau,
  213. Bellinzona,
  214. Geneve 14,
  215. Locarno,
  216. St. Gallen,
  217. Maidstone, Kent
  218. Wolverhampton, West Midlands
  219. Edmonton,
  220. Leicester,
  221. London,
  222. Manchester,
  223. Manchester,
  224. Manchester,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Non-Small Cell Lung CancerStudy Tests The Safety And Effectiveness Of SU011248 In Patients With Non-Small Cell Lung Cancer Having Brain Metastases NCT00372775
  1. Norwalk, Connecticut
  2. Cocoa Beach, Florida
  3. Merritt Island, Florida
  4. Titusville, Florida
  5. Creve Coeur, Missouri
  6. St. Louis, Missouri
  7. St. Louis, Missouri
  8. St. Peters, Missouri
  9. Basking Ridge, New Jersey
  10. Commack, New York
  11. New York, New York
  12. Sayre, Pennsylvania
  13. Austin, Texas
  14. Austin, Texas
  15. Austin, Texas
  16. Austin, Texas
  17. Round Rock, Texas
  18. Pessac, Be1 04495
  19. Marseille Cedex 09,
  20. Saint-Priest en Jarez Cedex,
  21. Toulouse cedex 9,
  22. Bologna,
  23. Genova,
  24. Orbassano (TO),
  25. Roma,
  26. Madrid,
  27. Valencia,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Non-small Cell Lung CancerA Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen NCT00769067
  1. Muscle Shoals, Alabama
  2. Montebello, California
  3. Bridgeport, Connecticut
  4. Norwalk, Connecticut
  5. Waterbury, Connecticut
  6. Atlanta, Georgia
  7. Atlanta, Georgia
  8. Atlanta, Georgia
  9. Atlanta, Georgia
  10. Atlanta, Georgia
  11. Augusta, Georgia
  12. Augusta, Georgia
  13. Columbus, Georgia
  14. Decatur, Georgia
  15. Gainesville, Georgia
  16. Macon, Georgia
  17. Marietta, Georgia
  18. Warner Robins, Georgia
  19. Post Falls, Idaho
  20. Post Falls, Idaho
  21. Zion, Illinois
  22. Bethesda, Maryland
  23. Rockville, Maryland
  24. Minneapolis, Minnesota
  25. Memphis, Tennessee
  26. Clarksburg, West Virginia
  27. Camperdown, New South Wales
  28. Fitzroy, Victoria
  29. Geelong, Victoria
  30. Wodonga, Victoria
  31. Porto Alegre, RS
  32. Porto Alegre, RS
  33. Barretos, SP
  34. Sao Paulo, SP
  35. Vancouver, British Columbia
  36. Barrie, Ontario
  37. Oshawa, Ontario
  38. Ottawa, Ontario
  39. Shatin, New Territories
  40. Tuen Mun, New Territories
  41. Seoul,
  42. Seoul,
  43. Seoul,
  44. Chrzanow,
  45. Krakow,
  46. Krakow,
  47. Krakow,
  48. Warsaw,
  49. Warszawa,
  50. Ponce,
  51. Singapore,
  52. Badalona, Barcelona
  53. Palma de Mallorca, Islas Baleares
  54. Barakaldo, Vizcaya
  55. La Coruña,
  56. Taipei,
  57. Taipei,
  58. Manchester,
  59. Oxford,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title Retrospective Epidemiology Study Of ALK Rearrangement In Non-Small Cell Lung Cancer Patients In The Middle East & North Africa
Official Title RETROSPECTIVE EPIDEMIOLOGY STUDY OF ALK REARRANGEMENT IN NON-SMALL CELL LUNG CANCER PATIENTS IN THE MIDDLE EAST & NORTH AFRICA.
Brief Summary Thet study aims to estimate the prevalence of ALK rearrangement in the Middle East North Africa population by using the Ventana ALK-IHC method for ALK protein detection in retrospective NSCLC clinical samples, & to evaluate the association of ALK rearrangement with clinical and pathological parameters of NSCLC patients in MENA.
Detailed Description

This is a retrospective, cross-sectional non-interventional epidemiology study to investigate the prevalence of ALK rearrangement in NSCLC patients in Middle East & North Africa. Approximately 700 retained tumor tissue specimens (tissue block) of patients previously diagnosed with NSCLC will be selected & subjected to ALK immune-staining using Ventana anti-ALK (D5F3) Rabbit Monoclonal Primary Antibody combined with OptiView Benchmark System in 6-8 centers in 5-7 countries in the MENA region.

The tissue samples of NSCLC cases will be retrieved from tissue banks of the molecular diagnostic units & pathology departments in these study centers. The histological diagnosis will be confirmed by the pathologists. The retained samples will then be tested by performing the Ventana ALK-IHC to assess the absence or presence of the ALK rearrangement by the detection of the ALK protein in formalin-fixed, paraffin-embedded NSCLC stored tissue samples using Ventana anti-ALK (D5F3) Rabbit Monoclonal Primary Antibody (Roche Diagnostics GmbH) in the selected study centers. The results of ALK testing within this study population will then be used to establish the prevalence of ALK rearrangement in MENA NSCLC patients.

The patients' characteristics, demographic, clinical and pathologic parameters will be obtained from their medical records & analyzed to determine any association with the presence of the EML4-ALK fusion gene in MENA NSCLC patients.

The assessment of concordance of the results between FISH & IHC will be done in 2-3 centers. Results of FISH testing will be collected & recorded, if the retained tissue samples had been previously tested. If not, the Vysis FISH test will be performed, to assess the concordance between the results obtained using Vysis Break-apart FISH & Ventana IHC testing methods for ALK rearrangement detection.

Study Type Observational
Study Design Observational Model: Other
Time Perspective: Retrospective
Target Follow-Up Duration Not Provided
Biospecimen Retention:   Samples With DNA
Description:
The tissue samples of NSCLC cases will be retrieved from tissue banks of the molecular diagnostic units & pathology departments in these study centers. The histological diagnosis will be confirmed by the pathologists. The retained samples will then be tested by performing the Ventana ALK-IHC to assess the absence or presence of the ALK rearrangement by the detection of the ALK protein in formalin-fixed, paraffin-embedded NSCLC stored tissue samples using Ventana anti-ALK (D5F3) Rabbit Monoclonal Primary Antibody (Roche Diagnostics GmbH) in the selected study centers.
Sampling Method Non-Probability Sample
Study Population Since this is a retrospective epidemiology study, no patients will be enrolled. Tissue samples of non-squamous NSCLC cases less than 5 years old from each of the centers will be selected.
Condition Non-small Cell Lung Cancer
Intervention Not Provided
Study Groups/Cohorts Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Completed
Actual Enrollment
 (submitted: October 24, 2018)
449
Original Estimated Enrollment
 (submitted: December 1, 2014)
700
Actual Study Completion Date February 11, 2018
Actual Primary Completion Date February 11, 2018   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

- 1. Histological confirmation of nonsquamous NSCLC, with any TNM stage. 2. Available and sufficient tissue sample for ALK testing 3.Tissue samples are less than 5 years old 4.Routinely processed formalin-fixed, paraffin-embedded tissue samples only (see exclusion criteria pertaining to tissue samples).

5.Histological sections mounted on glass slides must not be older than 3 months 6.Age > 18 years 7.Any ECOG Performance status 8.Still alive, or death confirmed before inclusion, or is unknown 9.Disease diagnosis and/or treatment in one of the centers, in the last 5 years, assigned to participate in the study; 10.Written informed consent for general investigational testing was previously obtained, or specifically obtained for this retrospective epidemiology study, or having a documented waiver for the Informed consent document use, as required by local regulatory authorities, &/or Research Ethics committee/Institutional Review Board.

Exclusion Criteria:

  • 1- Tumor tissue samples older than 5 year period or samples not properly stored.

    2-Tumor tissue samples fixed by using AFA, B5, Bouin's, 95% ETOH, & alcohol fixatives.

    3-Under-fixed tissue samples (i.e. < 6 hrs) 4-Tumor tissue samples that have been subject to any decalcification processes. 5-Recycled paraffin-embedded tissue samples. 6-Cut slides stored longer than 3 months. 7-Insufficient tissue samples with less tumor cells & high amount of necrosis.

Sex/Gender
Sexes Eligible for Study:All
Ages 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Egypt,   Lebanon,   Morocco,   Saudi Arabia,   United Arab Emirates
Removed Location Countries  
 
Administrative Information
NCT Number NCT02304406
Other Study ID Numbers A8081046
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement
Plan to Share IPD:No
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
Responsible Party Pfizer
Study Sponsor Pfizer
Collaborators Not Provided
Investigators
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date May 2019